Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization
Klaska, I.P. (Guy's Hospital, Great Maze Pond, London, UK)
White, Anne (University of Manchester, UK)
Villacampa, Pilar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Hoke, Justin (University College London, UK)
Abelleira-Hervas, Laura (University College London, UK)
Maswood, Ryea N. (University College London, UK)
Ali, Robin R. (Guy's Hospital, Great Maze Pond, London, UK)
Bunce, Catey (King's College London, Addison House, London, UK)
Unwin, Richard D. (University of Manchester, UK)
Cooper, Garth J.S. (University of Manchester, UK)
Bishop, Paul N. (Manchester University NHS Foundation Trust, UK)
Bainbridge, James W. (University College London, UK)

Data:	2022
Resum:	Opticin is an extracellular glycoprotein present in the vitreous. Its antiangiogenic properties offer the potential for therapeutic intervention in conditions such as proliferative diabetic retinopathy and retinopathy of prematurity. Here, we investigated the hypothesis that intravitreal administration of recombinant human opticin can safely protect against the development of pathological angiogenesis and promote its regression. We generated and purified recombinant human opticin and investigated its impact on the development and regression of pathological retinal neovascularization following intravitreal administration in murine oxygen-induced retinopathy. We also investigated its effect on normal retinal vascular development and function, following intravitreal injection in neonatal mice, by histological examination and electroretinography. In oxygen-induced retinopathy, intravitreal administration of human recombinant opticin protected against the development of retinal neovascularization to similar extent as aflibercept, which targets VEGF. Opticin also accelerated regression of established retinal neovascularization, though the effect at 18 h was less than that of aflibercept. Intravitreal administration of human recombinant opticin in neonatal mice caused no detectable perturbation of subsequent retinal vascular development or function. In summary we found that intraocular administration of recombinant human opticin protects against the development of pathological angiogenesis in mice and promotes its regression.
Nota:	Altres ajuts: Medical Research Council (grant no. MR/M025365/1)
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Opticin ; Angiogenesis ; Neovascularization ; OIR ; PDR ; ROP
Publicat a:	Experimental Eye Research, Vol. 215 (february 2022) , ISSN 1096-0007

DOI: 10.1016/j.exer.2021.108908
PMID: 34954204

8 p, 6.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats